Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.



Aug 1, 2018 18:35 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
HitBTC Announces PASS Token Listing  
Oct 23, 2018 23:30 HKT/SGT
Hong Kong Optical Fair Opens on 7 Nov  
Oct 23, 2018 19:00 HKT/SGT
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide  
Oct 23, 2018 14:13 HKT/SGT
Hitachi Appoints Partners to Support Wylfa Newydd  
Oct 23, 2018 09:22 HKT/SGT
NTT DOCOMO Launches IoT-driven Temperature-Monitoring Service in USA  
Oct 23, 2018 08:05 HKT/SGT
AIR Develops Advanced Probabilistic Model for Global Cyber Risks  
Oct 22, 2018 18:00 HKT/SGT
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan  
Oct 22, 2018 16:34 HKT/SGT
Asian Logistics and Maritime Conference Opens 20 Nov  
Oct 22, 2018 16:30 HKT/SGT
iCard and myPOS enable JCB Contactless acceptance in Europe  
Oct 22, 2018 16:00 HKT/SGT
Reinforce Your Portfolio by Diversifying into Iron Ore -- SECFilings.com  
Oct 22, 2018 15:00 HKT/SGT
More Press release >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: